chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At injection site - hotness; Skin hardness at injection site; Extreme pain at injection site; Redness at injection site that has spread; This is a spontaneous case from, initially received from other health professional via agency (case ID: SEQ19-04875) on 16-Oct-2019, concerning a male patient of an unknown age.   The patient's medical history and concomitant medications were not reported.   On an unknown date, the patient was administered Afluria Quadrivalent [influenza vaccine, dose: 0.5 ml, batch number: P100112490, expiration date: 11-Jun-2020, route of administration and anatomical location: not reported] for an influenza prophylaxis.  On an unknown date, after vaccination, the patient experienced hotness, extreme pain, skin hardness at injection site and redness at injection site that had spread.   On 24-Sep-2019, the reporter stated that the patient was doing well.  The outcome of all the events was recovered, on an unspecified date.  The reporter did not provide seriousness and causality assessment.  The case is linked to 201905307, 201905317, 201905318, 201905319, 201950320, 201905321, 201905322, 201905323 and 201905324 due to same reporter.  Follow up received from other health professional via agency (SEQ19-05499) on 24-Oct-2019: The reporter stated that all vaccine recipients were doing well. The outcome of all events updated to 'Recovered/resolved'. Narrative amended accordingly.  Company comment: The patient experienced vaccination site warmth, vaccination site induration, vaccination site pain and vaccination site erythema after vaccination with the suspect product Afluria Quadrivalent. Chronology is plausible. No medical history, diagnostic findings and concomitant medications were reported. Considering all the above mentioned, causal role of the suspect product cannot be totally excluded and is assessed as possibly related.; Sender's Comments: The patient experienced vaccination site warmth, vaccination site induration, vaccination site pain and vaccination site erythema after vaccination with the suspect product Afluria Quadrivalent. Chronology is plausible. No medical history, diagnostic findings and concomitant medications were reported. Considering all the above mentioned, causal role of the suspect product cannot be totally excluded and is assessed as possibly related.
Received Pfizer covid vaccination 12/28/20 and 1/18/21.  Fully vaccinated and diagnosed Covid (+) 09/13/2021
Received cover shot on 3-17 and at 2am on 3-18 I woke up and could not move my left arm.  Thinking the arm was asleep, I attempted to move it with the opposite hand and extreme pain resulted from the slightest movement.  I noticed the bandage covering the injection site was high up on the shoulder about 1 finger width below the boney point of the shoulder.  I began doing daily stretches /exercises to try to regain mobility in the left arm.  After about 3 weeks there was some improvement in mobility but still pain with many movements.  I began researching arm pain following covid vaccine and discovered there can be injury caused by vaccines being injected too high, above the muscle.  I contacted my Dr's office and asked for advice on what to do next to improve my arm function.  Physical therapy was suggested.  I received my second covid dose on 4-14-21. I spoke to the RN administering the 2nd dose about my previous shot.  She said it likely was injected into the rotator cuff area from my description of where the bandage was located.  She measured 3 finger widths down from the boney point and injected into the muscle.  I did not have any worsening  mobility issues from the second dose.  I started physical therapy on 4/22/21 and go twice a week.  The physical therapist thinks I have an impingement.  Since beginning physical therapy, I have had some mobility improvement and pain is better but still not fully recovered.
patient is a lung transplant patient and had previously had pneumovax 23 in 2016. He request pneumovax per md but was only 63 and should have received pneumovax at 65 years of ago.---no adverse reaction
Experienced severe redness about 2.5-3? in diameter around vaccination administration site Area was very swollen, warm to the touch, tough, and incredibly painful which caused me to have difficulty moving my arm/using my arm in general and limited my normal daily activities for 4 total days. Pain, swelling, redness, and toughness began to dissipate around Day 5 and was markedly improved by Day 8 when I completely returned to normal activities.  Additionally, the first day after the vaccination, I experienced muscle aches/pains and severe generalized fatigue that almost made me call out from work. This fatigue and muscle pain was very strong for ~72 hours after the vaccination. However, I was still able to go to work, though my productivity was not the same given the amount of fatigue I experienced and the inability to utilize my right arm to the same degree I would during a normal work day.
Pt received her Pfizer booster and 5 minutes later  complained of lightheadedness and dizziness.  Abruptly had pt in supine position and administered  8 oz of water x2, cold compress applied to forehead, and open windows for ventilation. Observed pt throughout , performed vital check every 15 minutes, and performed safety check. Pt at bedside with  mother, nurse, and supervisor. Reports improvement in symptoms 45 minutes later and was escorted by mom out of facility.
15 hours after the vaccine was received I started to experience a migraine-like headache, nausea and muscle aches.
Next morning follwoing immunization father noted rashy bumps on neck back and stomach. Called Dr and Dr said just watch him. Dr is the family Dr. As of 11/13/2008 bumps remain but rash color is gone per mother.
patient received Sinopharm covid vaccine Jan 8 2021 and Feb 5 2021 in another country. Received Moderna #1 at  11/17/21 and second shot 12/15/21. Shortly after second dose 12/15/21 he felt feverish but this mostly resolved. This AM, 12/16/21, noted chest pain and shortness of breath, pressure substernally, and racing heartbeat 'over 100'. On exam about 11 am 12/16/21 he had heart rate 94-102, normal EKG. Sent to the Hospital  for echo and troponins, etc with suspected pericarditis vs anxiety
Small burning blisters on neck, behind ears. Under chin/jaw. Up cheeks. Around hair line, brows/eyes.
Concomitant products included HYDROCORTISONE (CORTAID INTENSIVE THERAPY) and LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) for an unknown indication.    On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE RASH (red dots like rash). On an unknown date, the patient experienced SKIN REACTION (localized and measures 3 cm wide and 5 cm tall), VACCINATION SITE PRURITUS (some itchiness), VACCINATION SITE PAIN (burning/soreness) and VACCINATION SITE ERYTHEMA (more red). At the time of the report, SKIN REACTION (localized and measures 3 cm wide and 5 cm tall), VACCINATION SITE RASH (red dots like rash), VACCINATION SITE PRURITUS (some itchiness), VACCINATION SITE PAIN (burning/soreness) and VACCINATION SITE ERYTHEMA (more red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       treatment product included HYDROCORTISONE (CORTAID INTENSIVE THERAPY) and LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) for an unknown indication For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
chest itching; shortness of breath; headache to front of head; elevated blood pressure at 169/92; This is a spontaneous report from a contactable other HCP.  A 54-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE)  intramuscular, administered in arm left, on 13Apr2021 12:47 (at the age of 54-year-old) (Lot Number: EN6200) as single dose for COVID-19 immunisation. Relevant medical history included chronic obstructive pulmonary disease, hypertension and cardiac failure congestive. The patient was not pregnant.  Concomitant medications included acetylsalicylic acid (ASPRIN); ciclesonide (ALVESCO); levosalbutamol hydrochloride (XOPENEX); all taken for unspecified indications, start and stop dates were not reported. The patient received vaccination at 12:47pm and began to have chest itching and shortness of breath at 12:53pm; the patient then came to clinic with elevated blood pressure at 169/92 and headache to front of head, 7/10 pain scale. The events resulted in Doctor or other healthcare professional office/clinic visit. The patient received treatment with paracetamol (TYLENOL) for headache. The patient had not recovered from the events. The patient did not have COVID-19 prior to vaccination; the patient was not tested for COVID-19 post vaccination.
In October 1991 & 1992 I had the flu shot. I got very sick within a week, developing bronchitis and asthma. In 1993, I was ill & had to take a medical leave of absence from Chronic Fatigue & Epstein Barr virus. My immune system was compromised. I later learned I have a dairy allergy including allergy to eggs. In 2003, I was at ER for cut to my finger. After receiving a tetanus shot, I had limited mobility in the arm vaccinated & pain for about a month. Soon after I had numbing in my feet & hands.
pt recv vax 14FEB97 & on 9MAR97  pt devel a varicella rash;10MAR97 pt was dx w/chickenpox;pt recovered;
Upper L arm very sore and is still sore all the time. During sleep, pain increases and arm "goes to sleep" numbness, loss of range of motion (after 5 mos.).
Felt like being in a fog; Dizziness; Very weak; Tiredness; Bad headache; Muscle pain; Chills; Fever from 100 to102.7 for 10 hours; Severe joint pain; Nausea; Swollen lymph nodes; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 01Apr2021 at 17:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and hypothyroidism. The patient had a history of allergy to sulfa. The patient had received medication within two weeks of vaccination which were unspecified. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 11Mar2021 at 17:15 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 17:45, the patient experienced tiredness, bad headache, muscle pain, chills, fever from 100 to102.7 (units not specified) for 10 hours, severe joint pain, nausea, swollen lymph nodes, dizziness, very weak and felt like being in a fog. The symptoms went on for 72 hours and reported that 108 hours after the 2nd dose the patient still felt very tired and had a few aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events tiredness, bad headache, muscle pain, chills, fever, severe joint pain, nausea, swollen lymph nodes, dizziness, very weak and felt like being in a fog was recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Flu-like symptoms; This case was reported by a pharmacist via call center representative and described the occurrence of influenza-like symptoms in a 73-year-old female patient who received Herpes zoster (Shingrix) (batch number 3HT5J, expiry date 26th January 2022) for prophylaxis.   On 20th July 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved.   It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The patient received the 1st dose of Shingrix in the left deltoid, since almost 90% of the doses they administered in the pharmacy were given in left deltoid. However, he did not have the documentation in front of him during this call and could not confirm for sure. The patient experienced flu like symptoms, that lasted a week. The patient was afraid to get the 2nd dose. The reporter consented to follow up. This case had been linked to the case US2019185189, reported by the same reporter.
While standing in line to schedule his second dose, the patient appeared to fall into the patient in front of him, in addition to landing on both his knees. After the event, the patient reported that after receiving the vaccine that he felt dizzy, and decided to sit down after receiving the vaccine in the waiting room. After a few minutes after feeling comfortable, the patient decided to stand up and get in line to schedule his second dose. He then proceeded to fall while waiting in line. He reported "seeing black" in addition to reporting sustained dizziness at the time of the fall. He also appeared to look pale. The patient was encouraged to lay supine as a wheelchair was brought to transport him from the waiting room to the urgent care for observation. The patient appeared to be in good spirits.
Narrative: Pt is a 95y.o. male who died on 02/02/2021 w/ h/o pernicious anemia, BPH, HTN, T2BM, GERD, HLD. Pt received Moderna Covid-19 Vaccine 1/2 on 01/16/2021. Pt died on 02/02/2021 at HOSPITAL. Unlikely that Moderna Covid-19 vaccine caused/contributed to pt death.
Received Benedryll 50mg IM.  Monitored for 1 hour. Released to home.
50 year old male received 3 anthrax vaccines while activated.  He noted bilateral shoulder joint pain that lasted approximately 3 weeks without any intervention.  In March 2004 he received anthrax vaccine #4.  Within 24 hours he had a recurrence of the bilateral shoulder pain and also muscle pain in the left shoulder.  The pain has not dissipated.  He has right knee and ankle pain that is related to a compound fracture sustained in 1986.  He has no other medical complaints.
Pt recv vax in 12/97; immediately post vax pt exp respiratory distress & nausea x 1 day
Patient was given 2nd dose moderna vaccine 5 days early. Currently no s/s or adverse reactions.
Developed extensive bruising, swelling, pain, to left deltoid, upper arm and numbness and tingling in her left wrist extending to her left thumb and index finger Patient is a 39 y.o. female with a past medical history of asthma and obesity who presents for evaluation of Chief Complaint Patient presents with Arm pain Reaction to covid injection Patient has swelling and bruising at the site of her recent COVID-19 injection given 2 days prior. She has been icing the area taking Motrin without relief. She has pain with movement of the arm and it seem to be worsening. She notes some numbness and tingling in her left wrist extending to her left thumb and index finger. She has a prior history of carpal tunnel. Blood pressure is well controlled today. No fever, chest pain, palpitation, shortness of breath. Exercise tolerance is stable. Tolerating medications well.
pt woke up 5NOV98 w/hives on lt side of abd & c/o nausea;went to Er was told it was a probable rxn to hep b vax;mom states pt given med for rash;
JUVENILE IDIOPATHIC ARTHRITIS AGGRAVATED/ POSSIBLE OUT GROWN JUVENILE IDIOPATHIC ARTHRITIS; IRREGULAR PERIODS; HEAVY PERIODS; GOT SICK WITH A FEVER; DENTAL FILLINGS; OFF LABEL USE IN UNAPPROVED AGE GROUP; This spontaneous report received from a patient via other manufacturer (AbbVie) concerned a 14 year old female. The patient's height, and weight were not reported.  The patient's concurrent conditions included: moderate to severe polyarticular juvenile idiopathic arthritis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, expiry: Unknown) dose was not reported, 1 total, administered on 10-MAR-2021 for covid-19 prophylaxis which was an Off label use (off label use in unapproved age group). The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Age at time of vaccination 14 years old. No concomitant medications were reported. Non-company suspect drugs included: adalimumab (solution for injection in pre-filled pen, subcutaneous, batch number: 1159243 and 1162439 expiry: UNKNOWN) dose was not reported, citrate free, frequency not reported, and therapy dates were not reported administered for moderate to severe polyarticular juvenile idiopathic arthritis.   On 28-JUN-2022, the patient experienced dental fillings.  On an unspecified date, the patient experienced juvenile idiopathic arthritis aggravated/ possible out grown juvenile idiopathic arthritis, irregular periods, heavy periods, and got sick with a fever.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and dose of adalimumab was not changed. The outcome of the irregular periods, heavy periods, dental fillings, juvenile idiopathic arthritis aggravated/ possible out grown juvenile idiopathic arthritis, got sick with a fever, and off label use in unapproved age group was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20220848362-covid-19 vaccine ad26.cov2.s-Juvenile idiopathic arthritis aggravated/ possible out grown juvenile idiopathic arthritis. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: UNDERLYING DISEASE. Therefore, this event(s) is considered not related.
Information has been received from a consumer concerning a female friend with latex allergy who was vaccinated with a dose of GARDASIL and was hospitalized (name, address and phone number unspecified) for a couple of days.  At the time of the report, the patient's status was unknown.  This is one of several reports received from the same source.  No further information is available.
All day (about 24 hr) low-grade fever - about 99.9 when usual is 97.6 (+ 2 degrees F) and overall headache  Self treated with Acetaminophen
SOB, generalized itchiness and raised red blotches - quarter size on left arm and right leg. Pt stated that these blotches were originally larger. Discharged from Urgent Care with prednisone, BENADRYL and an ointment. Followed up on 9/23 in employee health. Still has red blotches (less severe) no SOB.
Fatigue, arms began to swell, itchy rash appeared underneath the arm. Was put on antibiotics by healthcare professional.
she experienced symptoms like having water in her head/ She then added that another friend of her has the same problem. which severely affected her hearing.  She then added that another friend of her has the same problem.; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team and legal division.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEAD DISCOMFORT (non-serious), outcome "unknown", described as "she experienced symptoms like having water in her head/ She then added that another friend of her has the same problem."; HYPOACUSIS (non-serious), outcome "unknown", described as "which severely affected her hearing. She then added that another friend of her has the same problem".  Additional information: Added that another friend of her has the same problem.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. Sender's Comments: Linked Report(s): US-PFIZER INC-202300190377 same reporter/drug/AE, different patients.
Wondering if any other unusual growths or Cysts that formed around the lungs has ever been reported by anyone else.
Swelling and erythema at site, next day the arm in which vaccine was administered had a papular rash.  The following day the rash was gone from the administered arm and had appeared on the other arm.  The third day, the rash had spread to the trunk and legs and looked more like large hives.  Rash remains 7 days past administration.
This spontaneous report was received from a registered nurse refers to a two unspecified patient of unknown age who sometime in May 2012, were vaccinated subcutaneously with a dose of MMR II (dose and lot numbers not reported) that were reconstituted in an expired diluent. No adverse effects were reported. Attempts are being made to obtain additional information identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available. This is one of several reports from the same source. Additional information has been requested.
Within 10 minutes of vaccination, chest pressure and burning with shortness of breath. This lasted for around 12 hours. I also had extreme fatigue for 2 days
Pt reported her throat felt like it was swelling and she was having trouble swallowing at 12:28. Pt laid down on exam table. Medical provider and nurse called to room. Pt reported she could no longer swallow her secretions, was in visible distress reported that is was becoming more difficult to breathe. SpO2 remained stable. Pt has experienced anaphylactic reaction to avocados. Through shared decision-making, provider administered 1st dose of 0.3 mg epinephrine at 12:56. Pt unable to speak, confirmed mild improvement, but consented to 2nd dose of 0.3 mg epinephrine at 13:03 d/t persistent inability to swallow secretions and respiratory distress. 911 was called at 13:00, EMS arrived at 13:08, pt was taken to Hospital at 13:13.
Pregnant at second dose; This spontaneous prospective pregnancy case was reported by a pharmacist and describes the occurrence of MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant at second dose) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 0030L20A and 031L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LABETALOL and PRENATAL VITAMINS for an unknown indication.   On 20-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 26-Dec-2020 and the estimated date of delivery was 02-Oct-2021. On 29-Jan-2021, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant at second dose). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifth week of the pregnancy.  On 29-Jan-2021, MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant at second dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.